Codice QR

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies

BackgroundCD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies. Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and the extent of improvement using CD19 in combin...

Descrizione completa

Salvato in:
Autori principali: Xiaoshuang Yuan, Feiqing Wang, Peng Zhao, Bo Yang, Xu Yang, Ting Tian, Bingbing Li, Guangyang Liu, Sanbin Wang, Dongxin Tang, Zhixu He, Yanju Li, Yang Liu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2025-05-01
Serie:Frontiers in Immunology
Soggetti:
car-t
hematological malignancies
chimeric antigen receptor
immunotherapy
cancer therapy
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1577360/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi